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developed  –order  kinetic  models  have  opened  new  perspectives  in  the  treatment  of 25 
photoreaction kinetics that stands as the best known alternative to the classical approach. 26 
The –order kinetics have been applied here to Fluvoxamine (Fluvo) with the aim to set out 27 
a  detailed  and  comprehensive  procedure  able  to  rationalise 28 
photodegradation/photostability of drugs and propose a platform  for photosafety studies. 29 
Our  results  prove  that  drugs’  quantum  yields  (0.0016  < 	30 
Φ  <  0.43)  should  a  priori  be  considered  wavelength–dependent,  their 31 
photostabilisation (up to 75% for Fluvo) by means of absorption competitors could explicitly 32 
be  related  to  a  decrease  of  the  photokinetic  factor,  and  photoreversible  drugs  can  be 33 
developed into efficient actinometers (as Fluvoxamine in the 260–290 nm range). A pseudo–34 









1. INTRODUCTION  42 
A vast number of drugs have been shown to be adversely affected by light both in vivo and in 43 
vitro.1-4 Consequently, several studies have been devoted to the elucidation of the 44 
mechanisms, photo–products, kinetics and photoprotection strategies of such 45 
photodegradation reactions.5-7 Thus far, the kinetic analysis of these reactions has relied 46 
solely on the classical thermal zeroth–, first– and second–order reaction models.5,6 47 
Nevertheless, despite the fact that it soon became evident that such treatment strategies are 48 
not suited for photochemical reactions, they continued to be employed, mainly due to the lack 49 
of more adequate alternative treatments, procedures and methods. This situation has 50 
considerably limited the scope and reliability of drugs’ photodegradation and 51 
photostabilisation studies. The efforts that may have been devoted to proposing integrated 52 
rate–laws for photokinetic data that truly reflect the evolution of photoreactions are very 53 
scarce in the literature and predominantly based on approximations. This status quo is due to 54 
the tedious and mostly unsolvable mathematical hurdles encountered during integration of 55 
photoreactions’ differential equations.8,9 Recently, an approach was proposed whereby semi–56 
empirical rate–law model equations could be developed for photodegradation reactions. It has 57 
also been shown that such photoreactions obeyed a –order kinetics, with a quite different 58 
formulation to the classical ones.10,11 The –order kinetic models, which proved to 59 
successfully describe drugs’ photoreactions undergoing unimolecular or reversible 60 
isomerization,10,12 have considerably facilitated photostability investigations.  61 
Fluvo is a selective serotonin (5–hydroxytryptamine, 5–HT) neuronal re–uptake 62 
inhibitor (SSRI) used in the treatment of depression and anxiety.13-15 It has a few side effects16 63 
and little or no anticholinergic effect which makes it a much less hazardous drug than other 64 
antidepressants especially in overdose quantities.17,18 65 
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While this molecule is stable to hydrolysis,19 it undergoes reversible geometric 66 
photoisomerism under UV irradiation around the oxime linker group, Scheme 1.20 The 67 
occurrence of only one photoproduct (Z–Fluvo) was evidenced for the photodegradation of 68 
E–Fluvo.20,21 While a number of pharmacological experiments have failed to link the Z–69 
isomer to any phototoxicity, it was nonetheless found to be a 150–times less potent than its 70 
E–counterpart when tested on cortical synaptosomes.19,22 UVB irradiation was deemed 71 
responsible for E–Fluvo isomerisation and thus interaction of this type of radiation with 72 
Fluvo and subsequent isomerisation could occur even in vivo since UVB is able to reach 73 
blood vessels in the dermis.20 Incidentally, the occurrence of SSRIs in aquatic environments, 74 
wastewater and even drinking water sources has also been reported.23 As such, the study of 75 
the photodegradation kinetics of these drugs becomes important not only from a 76 
pharmacological but also from an environmental point of view.   77 
78 
Scheme 1: E/Z (Anti/Syn) reversible photoisomerism of Fluvo  79 
upon exposure to UV–irradiation. 80 
 81 
Very little is known on the photodegradation kinetics of Fluvo.20,21 Its 82 
photodegradation was attributed the pseudo–first order kinetics under fluorescent lamp 83 
irradiation (with a beam’s bandwidth of 110 nm, ranging between 290–400 nm with a 84 
maximum emission at 312 nm)21 and differing half–life times were recorded depending on 85 
the spectral output of the lamps used for irradiation.20 Relatively low quantum yield values of 86 












recorded for the experiment using irradiation light from fluorescent lamps.21 Nevertheless, to 88 
the best of our knowledge, neither quantum yield determination for the individual forward (E 89 
→ Z) and reverse (Z → E) reactions nor experiments involving UVB radiation have, thus far, 90 
been attempted. 91 
In this paper, the issues highlighted above have been addressed together with a 92 




2.  Materials and methods 95 
2.a  Materials 96 
Fluvoxamine maleate, 2–{[(E)–{5–Methoxy–1–[4–(trifluoromethyl)phenyl] pentylidene} 97 
amino]oxy}ethanamine (E–Fluvo), glacial acetic acid and Spectrophotometric grade 98 
acetonitrile were purchased from Sigma–Aldrich. Double distilled water was used as the 99 
solvent. 100 
 101 
2.b  Monochromatic continuous irradiation 102 
For irradiation experiments, a Ushio 1000 W xenon arc–lamp light source housed in a 103 
housing shell model A6000 and powered by a power supply model LPS–1200, was used. 104 
This setting was cooled by tap water circulation through a pipe system. The lamp housing 105 
was connected to a monochromator model 101 that allows the selection of specific irradiation 106 
wavelenghths since it consists of a special f/2.5 monochromator with a 1200 groove/mm at 107 
300 nm blaze grating. The excitation beam was guided through an optical fibre to impinge 108 
from the top of the sample cuvette i.e. the excitation and the analysis light beams were 109 
perpendicular to each other. The set up (lamp, lamp housing and monochromator) was 110 
manufactured by Photon Technology International Corporation.  111 
 112 
2.c  The monitoring system  113 
A diode array spectrophotometer (Agilent 8453) was used to measure the various absorption 114 
spectra and kinetic profiles for the irradiation and calibration experiments. This 115 
spectrophotometer was equipped with a 1–cm cuvette sample holder and a Peltier system 116 
model Agilent 8453 for temperature control. As such, the sample was kept at 22C, stirred 117 
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continuously during the experiment, and completely shielded from ambient light. The 118 
spectrophotometer was monitored by an Agilent 8453 Chemstation kinetics–software. 119 
A Radiant Power/Energy meter model 70260 was used to measure the radiant power 120 
of the incident excitation beams.  121 
 122 
2.d  Kinetic data treatment 123 
In order to carry out non–linear fittings and to determine best–fit curves, a Levenberg–124 
Marquardt iterative program within the Origin 6.0 software was used. 125 
 126 
2.e  HPLC measurements 127 
The HPLC system consisted of a reversed–phase Jupiter 5μ C–18 300A Phenomenex (250 x 128 
4.60 mm) column equipped with Perkin Elmer Series 200 pump, UV/Vis detector, vacuum 129 
degasser and a Perkin Elmer type Chromatography Interface 600 series Link linked to a 130 
computer system. 131 
The mobile phase consisted of 60 % double distilled water adjusted to pH 4.8 with 132 
glacial acetic acid and 40 % acetonitrile. A flow rate of 1.5 ml/min and an injection loop of 133 
20 l were used. The detector wavelength was set at 245 nm. Retention times of 10 and 8.32 134 
min were recorded for E and Z isomers, respectively.  135 
 136 
2.f  Fluvo solutions 137 
A 2.88 x 10–4 M stock solution of Fluvo in water was prepared by weighing the solid. The 138 
flask was protected from light by aluminium foil wrapping and was kept in the fridge. The 139 
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stock solution was diluted to prepare fresh analytical solutions (ca. 2 x 10–6 M) for analysis of 140 
irradiation experiments performed at various wavelengths. 141 
For actinometric studies, Fluvo solutions of the same concentrations (ca. 2.9 x 10–6 142 
M) were exposed to specific wavelengths irradiations (260, 270, 280, 285 and 290 nm) using 143 
a series of different intensities for each wavelength. The kinetic traces were observed at the 144 
observation wavelength = 245 nm and subsequently fitted with the –order equations. 145 





3. RESULTS AND DISCUSSION 149 
3.a  The Mathematical background 150 
3.a.1–Order kinetics for non–isosbestic irradiation 151 
The kinetic data of direct unimolecular photoreactions and photoreversible dimolecular 152 
phototransformations, collected at non–isosbestic and monochromatic irradiation at constant 153 
temperature, have recently been shown to obey –order kinetics.8,10-12 –order kinetics is 154 
much more suitable to describe photoreactions than the classical treatments proposed for 155 
zeroth–, first– and second–order thermal reactions. Even though ubiquitous, the treatment of 156 
photokinetics on the basis of the latter classical reaction orders is unreliable, for at least three 157 
main drawbacks inherently linked to this approach. Firstly, the differential equations of 158 
photoreactions are generally different from and not possibly integrated in closed–forms as is 159 
the case for thermal reactions of 0th–, 1st–or 2nd– order. This means that using such classical 160 
orders’ treatments for the quantitative investigation of photoreactions must be considered as a 161 
mere approximation. Secondly, literature data have reported that the classical approach may 162 
lead to a confusion about the reaction order that should be attributed to the photodegradation 163 
reaction at hand given that the kinetic data of a given reaction (generally up to half–life time) 164 
can well be fitted by the equations corresponding to two different reaction orders (most 165 
commonly 0th– and 1st–order). Thirdly, the rate–constant values determined from the 166 
experimental data of photodegradation cannot be analytically linked to the experimental 167 
conditions and/or reaction attributes. This has made it difficult to compare such rate constants 168 
between compounds and/or laboratories.  169 
In this context, the approach adopted to develop the equations of –order kinetics 170 
offers a more robust mathematical framework to investigate photoreactions. The model 171 
equation, a logarithmic expression involving a time–dependent exponential term, for 172 
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unimolecular photoreactions where only the initial species absorbs, have been derived 173 
through closed–form integration.8 This model equation has represented the basis to develop 174 
the semi–empirical model equations for both the unimolecular photoreaction where both 175 
initial species and photoproduct absorb, and photoreversible reactions. They have been 176 
optimised by studying simulated photoreaction traces obtained by numerical Runge–Kutta 177 
integration methods.10,11 These traces, calculated for a wide range of experimental conditions 178 
for unimolecular10 and reversible photoreactions,11 served for referencing the reliability and 179 
validation of the proposed semi–empirical integrated rate–laws.  180 
A unique set of general equations (Eqs. 1a,b) can be derived for photochemical 181 
reactions involving two species, the initial molecule, A, and its photoproduct, B, whose 182 
transformations might be achieved by one ( → ) or two ( ⇌ ) photochemical steps, 183 
each one characterised by a specific photoreaction quantum yield (AB  and  BA). Such 184 
systems are labelled as AB(1) and AB(2), respectively. Hence, if assumed that the 185 
concentration of the excited state is negligible during the progress of the photoreaction while 186 
the reaction medium is concomitantly maintained at a constant temperature, homogeneously 187 
stirred, and continuously irradiated with a monochromatic beam (with the latter beam’s non–188 
isosbestic wavelength (irr) correspond to a spectral region where species A and B absorb 189 
different amounts of light ( ), i.e., the absorption coefficients ( ) of the species are different 190 
and might have non–zero values (  	    0)), then in these conditions, the 191 
concentration profiles,  and ,  are dependent on the species absorption 192 
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were ⇋  is the overall reaction rate-constant, and  is the optical path length of the 196 
excitation light across the reactive medium.  197 
For spectrophotometric monitoring of the reaction’s evolution, it is preferable to use 198 
the logarithmic integrated rate–law equation describing the variation of the total observed 199 
absorption ( / ) with time:11     200 
 201 
/ / ∞
/ 0 / ∞
/ 0 / ∞
	 1 10
/ /
1 ⇋ 							 2  
 202 
Eq.2 involves only the cumulative observed absorbances ( / ) of the medium 203 
which have been measured under the observation ( ) and not the excitation ( ) 204 
condition (with  being the optical path length of the monitoring light inside the sample). 205 
These optical path lengths (  and ) are not necessarily equal for a given experiment, 206 
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and the absorbance of the medium in the excitation conditions (i.e. corresponding to a 207 
measurement along ) may not be directly accessible during the experiment.  208 
The coefficients / , / 0 , / , / 0  and 209 
/  in Eq.2 are the measured (along ) total absorbances of the medium 210 
respectively recorded at reaction time t, at the initial time (t = 0) and either at the end of the 211 
reaction or at the photostationary state (pss, where t = ). The reaction medium is irradiated 212 
at a given irradiation wavelength and simultaneously monitored at either a different 213 
observation wavelength ( / ) or at the same wavelength ( / ). It is assumed that 214 
the reaction is quantitative and proceeds without by–products.  215 
The analytical expression of the exponential factor, ⇋ , in Eqs.1 and 2 which 216 
represents the overall reaction rate–constant, is given by,11  217 
 218 
⇋ Φ → Φ → ∞ 														 3        219 
 220 
where  Φ →  and Φ →  are the forward and reverse quantum yields of the reaction 221 
photochemical steps realised at the irradiation wavelength ( );  is the radiant power 222 
(expressed in einstein dm-3 s-1);   is a proportionality factor, and ∞  the time–223 









As it has been previously shown,11 Eq.2 describing the kinetics of AB(2) systems, 226 
can also allow retrieving the equations set out for pure unimolecular AB(1) reactions 227 
(Φ → 0), where either (i) only the initial compound absorbs the irradiation light (in these 228 
conditions / ∞ 0  and ∞ 2.3	 ≅ 10 )8,24 or (ii) both the initial 229 
compound and its photoproduct (A and B) absorb light at the irradiation wavelength (which 230 
corresponds to complete depletion of species A, and therefore, ∞  is calculated using 231 
Eq.3 with / ∞ / ∞ 	 0 ).10 232 
The differentiation of Eq.2 yields the expression of the initial velocity of the reaction 233 
⁄ 	 .
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The numerical value of Eq.5, obtained graphically, corresponds to the theoretical 236 
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 238 
When calculating 	 .
/ , the photokinetic factor  at time t = 0 takes the value of 239 
0 , that is determined using / 0 0  in lieu of 240 
/ ∞  in Eq.4.  is a proportionality factor. 241 
Because Eqs.1 and 2 are semi–empirical, their application has been limited to 242 
∞  values higher than 1.2. This condition is easily met by reducing the values of either 243 
the initial concentration of species A or the optical path length for irradiation, .10,11  244 
 245 
3.a.2  Isosbestic irradiations equations  246 
In the case where the monochromatic irradiation of the solution is realised at an isosbetic 247 
point,  (only a few isosbestic points are usually present on the electronic spectra 248 
of AB(2) reactions), the general integrated rate–law of AB reaction systems has been 249 
obtained through a closed–from integration,25 as 250 
∞ 0 ∞ ⇋ 																																																																				 7     251 




with ∞  and ∞ , the concentrations of the species at either the end of the reaction or 253 
pss (t = ∞) and ⇋ , the overall rate–constant of the reaction performed at an isosbetic 254 
irradiation. 255 
⇋  has the same analytical expression as Eq.3 but with   replacing   and 256 
the photokinetic factor  used instead of ∞ .  is calculated using Eq.4 with 257 
/  instead of  / ∞ .  258 
The value of the initial velocity can be obtained graphically and compared to its 259 




⇋ 0 Φ → 0 			 9 	 
 262 
The monoexponential form of the equations 7 and 8 indicates that isosbestic 263 
irradiations induce first–order kinetics for AB(2) reactions. This is primarily due to the fact 264 
that when  , the photokinetic factor does not vary with reaction time (as the 265 
medium absorbance at the irradiation wavelength, , is time–independent).  266 
 267 
3.a.3  The kinetic elucidation method for AB(2) photoreversible reactions 268 
If, a priori, we suppose that the quantum yields of the photoreaction are wavelength–269 
dependent (until proven otherwise) and the spectra of the species A and B overlap, then the 270 
equations set out above for both isosbetic (Eqs.7 and 8) and non–isosbestic (Eq.1 and 2) 271 
irradiations can fit well the AB(2) experimental traces obtained photometrically, however, 272 
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the extracted fitting parameters ( ⇋  and 	
/  or ⇋  and 	
/ ), which 273 
represent two equations for each irradiation condition, are not sufficient to work out the three 274 
unknowns of the reaction namely, its photochemical quantum yield values and the absorption 275 
coefficient, , (i.e. the electronic spectrum) of the photoproduct, if none of the latter is 276 
available prior to the experiment. Solving the kinetics by using only the fitting parameters 277 
(irrespective of the number of /  traces) leads to a degenerate kinetic solution with 278 
inextricable identifiability and/or distinguishability issues.26  279 
In order to overcome this situation, we have recently proposed a simple elucidation 280 
method for photoreversible reactions that can be implemented in three steps.26   281 
  Firstly, the reaction quantum yields are determined for an isosbestic irradiation. The 282 
variation of the species concentrations during photodegradation, under a monochromatic 283 
irradiation at an isosbestic point, is monitored by HPLC. At the given irradiation wavelength 284 
( ), the absorption coefficient of the photoproduct is known ( ) and 285 
therefore, the number of unknowns is only two (Φ →  and Φ → ) for this experiment.  286 
Hence, fitting the experimental data with Eqs.7 and 8 provides the numerical values 287 
for the reaction initial velocity ( 	 , Eq. 9) and the reaction overall rate–constant ( ⇋ ). In 288 
these conditions, solving the system of two equations ( 	  and ⇋ ), leads to the 289 
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 292 
Both the species pss concentrations and the quantum yields’ values, allow determining the 293 









It is worth noticing that K⇋  is concentration–independent. This feature finds its 297 
importance in the fact that the HPLC experiment that served its determination is usually 298 
performed at initial concentrations of species A that are not suitable (too concentrated) for 299 
spectrophotometric analyses (which are bound to be realised at lower concentration, specifically, 300 
where ∞  > 1.2 as discussed above). 301 
The reconstruction of the full spectrum of the photoisomer (B), can then be performed at 302 
lower concentrations in the second step of the elucidation method. This is achieved from the value 303 
of K⇋  and the spectrum of the reactive medium recorded at pss under the same isosbestic 304 









Therefore, irrespective of the wavelength selected to perform the irradiation, the 309 
number of unknowns will constantly be two in total, as the spectrum of the photoproduct 310 
( ) is fully known. 311 
  Hence, in the last step of the method, the quantum yields for each non–isosbestic 312 
irradiation wavelength (Φ →  and Φ → ) can readily be worked out by using Eq.6 and its 313 
numerical value given by Eq.5 (for Φ → , Eq.14) and by rearranging Eq.3 (for Φ → ) to give 314 
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 318 
3.b  Fluvo photoreaction 319 
The native electronic absorption spectrum of E–Fluvo isomer (Fig.1) can be divided into two 320 
main absorption regions, 200–226 nm (Log()= 4.5) and 226–320 nm (Log()= 4.1). This 321 
molecule, thus, absorbs mainly in the UVB region of the spectrum as it is the case for non–322 
conjugated oximes, with the long wavelength absorption transition having a →* 323 
character.27  When exposed to a monochromatic irradiation within that region, the spectrum 324 
of the solution decreases in the regions 200–215 nm and 226–285 nm and increases in the 325 
alternate regions of 215- 226 nm and 285-320 nm (Fig1). The clearly defined isosbestic 326 
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points (at 215, 226 and 285 nm) and the smooth evolution of the spectra indicate that the 327 
photoreaction is quantitative and proceeds without by–products. Furthermore, E–Fluvo and 328 
its photoproduct (Z–Fluvo, Scheme 1) share a similar overall spectral shape with a 40 % 329 
maximum variation in absorbance observed at ca. 245 nm. 330 
 331 
3.c  Determinaltion of the equilibrium constant at an isosbestic irradiation ( ⇋ ) 332 
An E–Fluvo aqueous solution was subjected to a 226–nm isosbestic/mononchromatic 333 
irradiation and the photoreaction was monitored by HPLC at various time intervals until the 334 
pss was reached. The concentration profiles of E– and Z–Fluvo were readily fitted by Eqs.7 335 
and 8 (Fig.2), and the fitting parameter, the rate–constant ⇋ , as well as the pss 336 
concentrations of the reactive species were determined. Subsequently, the forward (Eq.10) 337 
and reverse (Eq.11) quantum yield values as well as the equilibrium constant ⇋  (Eq.12), 338 
could be calculated (Table 1). At   = 226 nm, the initial E–isomer is found to be more 339 
than twice as photoefficient as its counterpart, as indicated by the value of K⇋ , which 340 
resulted, given that  = , in a higher proportion of the Z–isomer in the pss 341 
composition, as it is usually observed for trans–cis photoisomerization.28,29 342 
 343 
Table 1: Overall rate–constant and equilibrium constant for the photodegradation of an 344 
aqueous Fluvo solution (1.37 x 10-4 M) exposed to isosbestic monochromatic irradiation at 345 






















3.d  Recovery of the Z–isomer’s absorption spectrum 348 
Based on Eq.13, the spectrum of the medium at pss and the spectrum of the E–isomer, the 349 
electronic absorption spectrum (as absorption coefficients’ values) of the Z–isomer can be 350 
fully reconstructed (Fig. 3). 351 
 352 
3.e  Isomers’ quantum yields at non–isosbestic irradiation wavelengths 353 
Once the absorption spectrum of the Z–isomer was known, the two remaining system 354 
unknowns (Φ →  and Φ → ) could then be calculated for any irradiation wavelength using 355 
the quantum yield expressions given by Eqs.14 and 15. 356 
Seven monochromatic irradiations (  = 290, 285, 280, 270, 260, 245, and 226 nm) 357 
that span the isomers’ absorption spectra, were selected in this study. The kinetic traces were 358 
recorded at a unique observation wavelength  = 245 nm, that corresponds to the most 359 
extensive variation of the absorbance (Figs. 1 and 3). In general, a smooth decrease in 360 
absorption over irradiation time was observed eventually reaching a plateau region (Fig. 4), 361 
as suggested by HPLC measurements. This represents a typical behaviour of AB(2) 362 
systems,  which in turn corroborates the mechanism of Fluvo photodegradation (Scheme 1). 363 
This is also confirmed by the good fitting of the kinetic traces with the model equation, Eq.2, 364 
for all non–isosbestic irradiations. Therefore, Fluvo photoconversion obeys –order kinetics. 365 
The kinetic parameters determined for Fluvo photodegrdation (Table 2), indicate that 366 
the overall rate–constant of photoreaction increases with increasing irradiation wavelength 367 
(Table 2). However, as has been comprehensively discussed in previous studies,10-12    368 
dependence on a number of experimental parameters (Eq.3), such as  initial concentration and 369 
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irradiation  intensity,  reduces  its  ability  to  inform  about  the  intrinsic photoreactivity of the 370 
molecule. Therefore, it is mandatory to define, in subsequent steps, the absolute values of the 371 
photoreaction quantum yields at the selected wavelengths. 372 
The recommended hypothesis for this type of studies is that the quantum yields of drugs 373 
should a priori be supposed wavelength dependent and then test the hypothesis experimentally. 374 
 375 
Table 2: Quantum yields, overall rate–constant, absorption coefficient and initial velocity values 376 
for Fluvo photodegradation reactions under various monochromatic irradiations, as determined by 377 
the order kinetics.  378 
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→    →   
226  0.0393  6.09 x 10
‐7
  0.0420  0.000197  ‐2.20x10
‐6
  14254  13802  2.086  0.00383 ± 0.00003  0.00157 ± 0.00027 
245  0.0399  5.86 x 10
‐7
  0.0281  0.000268  ‐3.09x10
‐6
  13478  8273  2.095 0.00612 ±0.00042   0.0038 ± 0.001331 
260  0.0398  4.60 x 10
‐7
  0.0191  0.000380  ‐4.56 x10
‐6
  10687  4997  2.14 0.0128 ± 0.00064  0.0085 ± 0.00096 
270  0.0405  5.21 x 10
‐7
  0.0109  0.000670  ‐8.31 x10
‐6
  6679  1859  2.19 0.0361 ± 0.00195  0.025 ± 0.0035 
280  0.0398  5.51 x 10
‐7
  0.0031  0.000875  ‐1.28 x10
‐5
  3109  829  2.25 0.0931± 0.00275  0.0535±0.0127 
285  0.0400  4.70 x 10
‐7
  0.0031  0.00048  ‐1.32 x10
‐5
  1774  586  2.27 0.2167 ± 0.0059  0.0844 ± 0.0075 
290  0.0402  2.56 x 10
‐7
  0.0028  0.00152  ‐6.69 x10
‐6
  859  596  2.28  0.4349 ± 0.0205  0.0573 ± 0.0184 
 379 
 380 
It is clearly shown from the results of Table 2 that the forward quantum yield (Φ →  ) 381 
increases with increasing wavelength and was always higher than the reverse quantum yield 382 
(Φ → ). The most pronounced variation of the quantum yield ratios (1.4 > Φ → Φ →  > 7.6) is 383 
situated in the longest wavelength, 280 to 290 nm, region (ranging between 1.7 and 7.5), whereas, 384 
a much more modest change in its values is observed in the region 245-280 nm  385 
22 
 
(1.4 > Φ → Φ →  > 1.7). Furthermore, the evolution of the forward quantum yield values with 386 




0.07 400 e 0.13
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 389 
This advantageously enables the determination of E–Fluvo quantum yield at any desired 390 
wavelength using the sigmoid equation (Eq.16).  391 
The reverse quantum yield, on the other hand, follows a lower pattern with irradiation 392 
wavelength (Fig.5), with a 5.4–fold maximum span of variation for the recorded set of values 393 
(whereas 11.4 was recorded for the forward quantum yield). A similar behaviour has been 394 
observed for Montelukast.12 The differing magnitude of photo–efficiencies between E– and its Z–395 
Fluvo isomer might suggest a difference in the excited–state associated with each species. The 396 
more pronounced difference between the isomers’ quantum yields that was recorded in the longest 397 
wavelength region indicates that the excited–sate of lowest energy is much more efficient for E– 398 
than for Z–Fluvo. This finding might suppose a more important contribution of the n→* excited–399 
state in Fluvo phototransformation. In any case, the increase of quantum yields with irradiation 400 
wavelengths, observed for a number of drugs studied in our team, does not have at present a 401 
full/comprehensive interpretation. Overall, such results may illustrate a case where not only the 402 
chemical nature, the geometry of the molecule but also the irradiation conditions impact the drugs 403 
photochemical behaviour.  404 
The oxime group within E–Fluvo is found to be twice as photochemically efficient as 405 
the ethene bond in the stilbene–like Montelukast (Φ →  = 0.012–0.18).
12 In both these cases, 406 
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as well as for nifedipine,10 the results show a trend of higher forward quantum yield values 407 
for lower–energy excited–states.  408 
In terms of photostability, the photoreversibility has the advantage of limiting the 409 
depletion of the initial active ingredient to the amounts recorded at the pss, however, the pss 410 
concentration (Z/E) ratios for Fluvo isomers, 411 
C C Φ → ε Φ → ε , increases with wavelength from 412 
2.5 and reaches a value of 11.3 at 290 nm, which indicates a substantial degradation of the 413 
initial species (E–Fluvo). In the case of Fluvo, this represents a significant decrease in dosage 414 
as Z–Fluvo is biologically inactive,20 but could be a major issue if for other drugs the 415 
photoproduct is toxic. These results stress out the usefulness and necessity of a full kinetics 416 
elucidation of drug photodegradation. They also confirm that reliable conclusions about the 417 
photoreactivity of a compound can only be reached when using monochromatic irradiation 418 
coupled to a treatment using the –order kinetics. It is then reasonable to suggest that the 419 
ICH recommendations would benefit from introducing an element of photostability 420 
assessment of the drugs at low concentration in solution. Such data would not only shed light 421 
on the photokinetic behaviour and photodegradation parameters of the drug in vitro but also 422 
may lay down a platform for an understanding of the behaviour of drugs in vivo. Indeed, the 423 
distribution of the administered drugs in the skin and eyes of the patients occurs mostly at 424 
low concentration within biological fluids and tissues.3,4 Many studies have shown that both 425 
topical and systemic drugs can cause different conditions including photosensitivity and 426 
dermatoses in all-age patients including newborns.30-33 Even though an exact number of the 427 
drugs concerned has not yet been made available, it is nonetheless possible that a very high 428 
proportion of existing and future organic drugs, assuming a conservative hypothesis, absorb 429 
in the UVA–UVB ranges (some in the visible).3,4 These types of radiation traverse through 430 
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the skin with UVA wavelengths penetrating deep into the dermis.3,4,20 Hence, most of drugs 431 
can reach the excited–state from which they potentially can subsequently photoreact both in 432 
vitro and in vivo. It has been shown that despite that the absorption spectrum of Fluvo ends 433 
ca. 290 nm (Fig.3), exposing the solution of this drug to UVA–Visible light (simulating day 434 
light) also caused its degradation.21 As for most drugs, the variability/progress of the 435 
photodegradation depends also on the intensity of the light and/or the duration of the 436 
exposure. In this context, the FDA, EMEA and ICH have issued guidelines on the evaluation 437 
of the photosafety of all new systemic and topical  pharmaceuticals capable of absorbing 438 
within the UVB, UVA or visible regions with absorption coefficients above 1000 M-1.cm-1 as 439 
well as existing drugs when unaddressed photosafety concerns arise.34-36 The regulatory 440 
authorities and pharmaceutical industries increasingly recognise photo-induced 441 
pharmaceutical and cosmetic drugs’ reactions.3,4,37 In addition, the advent of an ever wide 442 
spreading phototherapy treatments (including home phototherapy),38,39 calls for clearer and 443 
tighter recommendations for photosafety testing. In this context, testing low concentrated 444 
solutions of drugs in vitro may arguably benefit the evaluation of the potential and extent of 445 
photodegradation that might be undergone by the drug in similar situations in vivo. The low 446 
concentration studies are also important because the equations of the –order kinetics (Eq.3) 447 
show that the rate of photodegradation of drugs increases with decreasing concentration.10 448 
Such low drug concentrations would mimic in vivo conditions as for the latter a maximum 449 
substrate concentration was set at 100 g/ml, in addition to a recommendation to perform 450 
several dilutions during the testing procedure.36 This is justified by the fact that most drugs 451 
reach the circulation, body tissues and eyes in significantly smaller amounts to the original 452 
given dose. Furthermore, the ICH currently recommends an irradiance dose of approximately 453 
5 J/cm2 UVA doses for the in vitro 3T3 Neutral Red Uptake phototoxicity test (3T3 NRU PT) 454 
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to corroborate natural irradiation conditions comparable to those obtained during prolonged 455 
outdoor activities on summer days around noon time, in temperate zones and at sea levels.36 456 
Therefore, the conditions of the present study reflect well the situation of drugs in the 457 
body as small concentrations (ca. 1.3 g/ml) and low radiation power (1-2 J/h/cm2) are 458 
employed. Such studies might be thought as a relevant initial platform, that provide reliable 459 
data and valuable information about the inherent photoreactivity of a molecule in solution, to 460 
feed the evaluation of drugs’ photosafety and photodegradation in vivo.  461 
 462 
3.f   Photostabilisation of Fluvo photodegradation using excipient–dyes 463 
There is an evident lack in the literature of useful methods to quantify photostabilisation of 464 
drugs. The Q1b document7 does not propose any detailed procedures in this respect including 465 
the case of solutions. In this section, the photoprotection of Fluvo with excipient dyes was 466 
assessed by –order kinetics.      467 
For this purpose, the UV–absorbing food additive/excipient–dye TRZ was selected as 468 
its spectrum overlaps that of Fluvo, hence acting as an absorption competitor. Its effect was 469 
evaluated on solutions of TRZ of various concentrations, which were each irradiated after the 470 
addition of the same amount of Fluvo. It is worth mentioning that prior to the addition of 471 
Fluvo, the TRZ solution was considered for the blank experiment on the UV/Vis diode array 472 
spectrophotometer. In these conditions, the temporal evolution of the absorbance of the 473 
medium could be recorded without the spectral interference of the dye (the latter however 474 
does absorb part of the excitation light).  475 
The resultant kinetic traces ( /  = 280/245) were fitted with Eq.2 (Fig.6) and 476 
their respective reactions rate–constants were determined (Table 3). Indeed, Eqs.1–6 apply 477 
except that the total absorbance of the medium at the irradiation wavelength in Eq.4 must take 478 
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into account the presence of the third molecule of the light–absorption competitor, i.e. the 479 
actual photokinetic factor, ⁄ , ∞ , involves / ∞ 	 /
/ ∞ / .   480 
The model equation (Eq.2) fitted well all the curves irrespective of the concentration of TRZ 481 
present in solution (though below the limit of its linearity range). Accordingly, the overall 482 
photoreaction rate–constant decreased with increasing TRZ concentration.  Up to 75% 483 
photostabilization of Fluvo was recorded for the highest TRZ concentration used in this study 484 
(4.68 x 10–5 M, Table 3). This confirms that the presence of the excipient–dye does not alter 485 
the photodegradation pattern and or quantum yields of the photoreactions but only reduces the 486 
rate of photodegradation. As stipulated by Eq.4., the photodegradation rate reduction is solely 487 
related to a reduction in the value of the photokinetic factor ( ⁄ , ) which itself is due to 488 
an effective increase of the medium absorbance at   /
/ ∞ / . 489 
   490 
Table 3: Dye absorbances, overall reaction rate–constants, photokinetic factors, and 491 
percentage reduction in reaction rates of Fluvo photodegradation in the presence of various 492 
concentrations of TRZ when irradiated at 280 nm and observed at 245 nm. 493 






















0.314 1.18 0.00051 1.71 41.4 
0.406 1.01 0.00044 1.98 49.4 
0.483 0.89 0.00037 2.32 56.9 
0.933 0.51 0.00022 3.87 74.1 
a: Absorbance of the dye measured at the irradiation wavelength of 280 nm for concentrations 494 
given in Fig.6.  495 
b: The constant concentration of Fluvo was 2.95 x 10–6 M.  496 
c: The radiant power value for the experiments was  = 5.06 x 10–6 – 5.18 x 10–6 497 
einstein.dm–3.s–1. 498 




Furthermore, as predicted by Eq.3, a good linear relationship was found between ⇋  501 
and ⁄ ,  (with intercept close to zero and a correlation coefficient close to unity) (Fig. 7). 502 
A similar phenomenon should also be expected to occur for an increase of the initial 503 
concentration of the mother compound (Eq.3), and hence, the rate of the reaction is 504 
concentration–dependent. This confirms that zero– and first–order reaction treatments and 505 
interpretation of photodegradation kinetics are neither suitable nor reliable approaches.  506 
The present –order kinetics equations offer however an easy and useful tool to 507 




An additional interesting and useful aspect offered by the equations of –order kinetics is the 512 
development of new actinometers. This may represent an important concept because no 513 
standard procedures have yet been established for the evaluation of drugs potential for 514 
actinometry and/or the proposal of new actinometers.5,6,40,41 Besides, the ICH adopted quinine 515 
hydrochloride actinometer holds a number of drawbacks that raised many of questions and 516 
doubts about its reliability.5,6,10,42-44   517 
The assessment of Fluvo potential for actinometry is set out by preparing solutions of 518 
approximately the same concentration and exposing each one to a monochromatic light of 519 
given radiant power values selected from a set for each irradiation wavelength (260, 270, 280, 520 
285 and 290 nm). The kinetic traces obtained at the observation wavelength of 245 nm were 521 
then well fitted to the model Eq. 2 (Fig.8). A linear correlation was observed between the 522 
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values of ⇋  and  for each set of irradiation experiments (Table 4) as predicted by 523 
Eq.2. Our experimental  and  values matched well those calculated from Eqs.3 and 6. 524 
 525 
 526 
Table 4: Correlation equations for the variation of the overall rate–constants 	and 527 
initial reaction velocities ( / ) with radiant power ( ), of Fluvo (2.95 x 10-6M) 528 
photodegradation in water ( = 2 cm; = 1 cm) together with the corresponding  529 
and  factors, 0 ,  and the span of radiant power employed for various 530 


















 	 		     
260 818.4 	3 10  0.99 2.136 2.199 2.93 – 4.60 
270 1249 3 10  0.96 2.194 2.244 2.50 – 5.21 
280 1584 	1 10  0.99 2.249 2.277 2.70 – 5.51 
285 1998 	2 10  0.98 2.273 2.287 2.63 – 4.81 
290 2077 5 10  0.99 2.284 2.291 2.56 – 4.42  
 / 	 		     
260 - 10.58 x  + 4.8x10-7 0.93 2.136 2.199 2.93 – 4.60 
270 - 14.57 x   8.9x10-7 0.98 2.194 2.244 2.50 – 5.21 
280 - 25.16 x  + 1.3x10-6 0.99 2.249 2.277 2.70 – 5.51 
285 - 28.11 x  + 1.8x10-7 0.99 2.273 2.287 2.63 – 4.81 
290 - 31.08 x  + 1x10-6 0.99 2.284 2.291 2.56 – 4.42 
a  , /  and intercepts expressed in s
-1






The gradients of the lines (of ⇋  vs. ), the beta factors ( ), represent 534 
constant coefficients that are independent of the light intensity for each irradiation 535 
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wavelength. Additionally, a linear correlation also exists between  	 .
/  and with 536 
gradients specific to each irradiation wavelength defined as the  factors (Table 4) as 537 
derived from the initial velocity Eq.6. The linear relationships found here confirm the 538 
usefulness of Fluvo for actinometry. 539 
Plotting the kinetic parameters and against irradiation wavelength, yield 540 
linear correlations, within the 260–290 nm irradiation range, as given by (Fig.9). 541 
The procedure for Fluvo–actinometry is set out on two simple strategies for the 542 
determination of the radiant power of an unknown source of light ( .) for the range 260–543 
290 nm. Firstly, (a)– a fresh solution of Z–Fluvo (3 x 10–6 M in water) is subjected to a 544 
monochromatic irradiation ( ) beam from the unknown source. (b)– The experimental 545 
kinetic trace hence obtained is fitted to Eq.2 and its ⇋  value determined; and/or the 546 
	 .
/  of the reaction is derived from the trace (Eq.5). In a third step, (c)– the 547 
corresponding values for the  and/or  factors are worked out from the corresponding 548 
relationships at  as given by the equations laid out in Fig.9. Finally, (d)– the unknown 549 




																																																																																																									 17 ,  
 552 
In order to facilitate even more the actinometric method, the , .
/  values 553 
calculated using Eq.6 were compared to those ( , .
/ ) obtained as the gradient of the 554 
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linear fit of the data corresponding to the early stages of the reaction (Fig.10). A very good 555 
agreement has been found, indicating that the initial velocity values can be worked out from 556 
the data corresponding to the first 5 to 10 min of Fluvo irradiation. This finding makes the 557 
development of AB(2) actinometers a less time–consuming process, which would be 558 
decisive for very slow reactions. 559 
Nevertheless, if the concentration or path–lengths used in the unknown light source 560 
experiment differ from the ones employed in this study (i.e. 2.95 x 10–6 M and  = 2 cm, 561 
respectively), then the must first be adjusted before being substituted in Eq.17a. This can 562 
be achieved by dividing the   value obtained in step (c) of the procedure above by 563 
2  (the latter corresponding to our experiment) and then multiplying it by the 564 
value of the new path–length and the photokinetic factor corresponding to the path–length and 565 
concentration used in the unknown light source experiment. Similarly, a correction is also 566 
needed for /  if different path-lengths and/or initial concentration were used. This can 567 
be achieved by dividing /  by 2 0  and then multiplying it by the values of the 568 
new path–length and initial photokinetic factor used. 569 
As well as facilitating actinometry studies, the can also serve to inform about a 570 
photoreaction rate much more reliably than the overall rate–constant or the quantum yields. 571 
Unlike  ⇋  and Φ , offers the possibility of comparing the rates of photoreactions 572 
within the same or different experimental settings employing the same initial concentrations. 573 
This is because  takes into account all photoreaction attributes and experimental 574 
parameters at the exception of the radiant power (which is hardly replicable   between 575 
experiments). This parameter is, therefore, an ideal tool for comparing the photoreaction rates 576 
between different experiments and we propose to label it as the “pseudo–rate–constant”. 577 
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(Similarly,  could be considered as a pseudo-initial velocity varying only with the terms 578 
given in Eq.6 but not with radiant power.) For instance, the wavelength causative range for 579 






. However, if the wavelength range was overlooked, the photodegradation of Fluvo is 10 581 
to 20 times slower than that of Montelukast with 1.7 10 2.8 10  (despite 582 
Φ → ,  >  Φ → , ).
12 Therefore, this parameter opens new perspectives in comparing 583 
photoreactions’ rates, which have long been awaited, since it is well documented that the  584 
(0th–, 1st–, or 2nd–order) overall rate–constant ( ) cannot be used comparatively between 585 
different experimental settings using the same or different photoreactive species.5 The 586 
quantum yield, on the other hand, informs specifically on the inherent efficiency of a 587 
molecule to photoreact in a particular solvent under a given irradiation wavelength, which 588 
would be proportional to the reaction rate if and only if the reactive species is the only 589 
compound absorbing the excitation light (Eq.3).8,10 However, the quantum yield value does 590 
not give a full picture on the photoreaction rate if there are more than one species absorbing 591 






The above study emphasises the new perspectives offered by the Ф–order kinetic model for 596 
photoreversible systems in general. For the particular case of drugs, it sets out a framework 597 
for targeted, accurate and complete kinetic studies. Ф–order kinetic then represents a more 598 
efficient tool for the assessment and quantification of both photosatbility and 599 
photostabilisation of drugs than the classical treatment based on 0th–, 1st– and 2nd–order 600 
kinetics. It can serve the development of new technological AB(2) devices in 601 
photomedicine, targeted drug delivery and photo–responsive drug nano–carrier systems.45-48 602 
The data provided by such studies may also be of importance for photosafety studies and 603 
might be recommended prior to conducting the evermore required  in vivo safety studies.  604 
Using Fluvo as an example of photoreversible reaction systems, the model (i)– fitted 605 
its full kinetic traces; (ii)– allowed the determination of the overall–rate constant; (iii)– 606 
offered the pseudo–rate–constant beta factors as a new  and reliable kinetic parameter truly 607 
reflective of intra– and inter–experiments’ rate of photoreactions; (iv)– allowed the 608 
quatification of effects of photostabilising additives; and (v)– presented Fluvo as an accurate 609 
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